Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Chundong Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7014-3611; OpenAlex author ID A5011546129. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 8

  1. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement. Co-author DOI 10.1038/s41388-025-03639-y↗
  2. Correction: UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-026-03696-5↗
  3. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc. Co-author DOI 10.1093/carcin/bgad076↗
  4. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  5. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  6. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  7. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.655152↗
  8. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-019-1278-9↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongze Chen · 6 shared papers, 2019–2026 · strength 0.90
  2. Bei Sun · 4 shared papers, 2019–2026 · strength 0.75
  3. Wenbo Yang · 4 shared papers, 2021–2026 · strength 0.69
  4. Danxi Liu · 4 shared papers, 2022–2024 · strength 0.67
  5. Zhongjie Zhao · 5 shared papers, 2019–2023 · strength 0.62
  6. Jisheng Hu · 5 shared papers, 2019–2023 · strength 0.62
  7. Yongwei Wang · 3 shared papers, 2023–2024 · strength 0.54
  8. Shangha Pan · 3 shared papers, 2022–2026 · strength 0.54
  9. Xuewei Bai · 2 shared papers, 2023–2026 · strength 0.42
  10. Le Li · 3 shared papers, 2022–2023 · strength 0.41
  11. Xinglong Geng · 3 shared papers, 2021–2023 · strength 0.41
  12. Guanqun Li · 3 shared papers, 2021–2023 · strength 0.41
  13. Bei Sun · 3 shared papers, 2021–2023 · strength 0.41
  14. Zonglin Liu · 2 shared papers, 2022–2024 · strength 0.38
  15. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  16. Chengxiao Yang · 1 shared paper, 2026 · strength 0.28
  17. Xinyuan Liu · 1 shared paper, 2026 · strength 0.28
  18. Le Li · 1 shared paper, 2026 · strength 0.27
  19. Hongze Chen · 1 shared paper, 2026 · strength 0.27
  20. Bei Sun · 1 shared paper, 2026 · strength 0.27
  21. Rui Kong · 2 shared papers, 2022–2023 · strength 0.27
  22. Tao Zhang · 2 shared papers, 2022–2023 · strength 0.27
  23. Yilong Li · 2 shared papers, 2019–2022 · strength 0.21
  24. Le Li · 2 shared papers, 2019–2021 · strength 0.21
  25. Zengfu Song · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.